Control of pain initiation by endogenous cannabinoids

Nature

Volumn 394, Issue 6690, 1998, Pages 277-281

  Calignano, Antonio ^a   La Rana, Giovanna ^a   Giuffrida, Andrea ^b   Piomelli, Daniele ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NEUROSCIENCES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; DEXANABINOL; FORMALDEHYDE; PALMIDROL; PHOSPHOLIPID; RIMONABANT; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; DRUG SYNERGISM; FORMALDEHYDE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MICE; PAIN; PALMITIC ACIDS; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

ANIMALIA; CANNABIS; PISUM SATIVUM;

EID: 0032537734     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/28393     Document Type: Article

References (29)

1. Martin, B. R., Balster, R. L., Razdan, R. K., Harris, L. S. & Dewey, W. L. Behavioral comparisons of the stereoisomers of tetrahydrocannabinols. Life Sci. 20, 565-574 (1981).
2. Martin, W. J., Lai, N. K., Patrick, S. L., Tsou, K. & Walker, J. M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 629, 300-304 (1993).
3. Tsou, K. et al. Suppression of noxious stimulus-evoked expression of FOS protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience 70, 791-798 (1996).
4. Lichtman, A. H., Cook, S. A. & Martin, B. R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 276, 585-593 (1996).
5. Herkenham, M. et al. Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA 87, 1932-1936 (1990).
6. Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K. & Walker, J. M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83, 393-411 (1998).
7. Devane, W. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
8. Richardson, J. D., Aanonsen, L. & Hargreaves, K. M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18, 451-457 (1998).
9. Di Marzo, V. et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691 (1994).
10. Fields, H. L. Pain (McGraw-Hill, New York, 1987).
11. Stein, C. The control of pain in peripheral tissue by opioids. New Engl. J. Med. 332, 1685-1690 (1995).
12. Dubuisson, D. & Dennis, S. G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4, 161-174 (1977).
13. Dickenson, A. H. & Sullivan, A. F. Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain 30, 349-360 (1987).
14. Rosland, J. H., Tjølsen, A., Maehle, B. & Hole, K. The formalin test in mice: effect of formalin concentration. Pain 42, 235-242 (1990).
15. Coderre, T. J. & Melzack, R. The contribution of excitatory amino acids to central sensitization and persistent nociception after formalin-induced tissue injury. J. Neurosci. 12, 3665-3670 (1992).
16. Rinaldi-Carmona, M. et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644-650 (1998).
17. Cravatt, B. F. et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87 (1996).
18. Beltramo, M. et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277, 1094-1097 (1997).
19. Cadas, H., di Tomaso, E. & Piomelli, D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17, 1226-1242 (1997).
20. Schmid, H. H. O., Schmid, P. C. & Natarajan, V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 80, 133-142 (1996).
21. Aloe, L., Leon, A. & Levi-Montalcini, R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions 39, C145-C147 (1993).
22. Mazzari, S., Canella, R., Petrelli, L., Marcolongo, G. & Leon, A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300, 227-236 (1996).
23. Facci, L. et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl Acad. Sci. USA 92, 3376-3380 (1995).
24. Showalter, V. M., Compton, D. R., Martin, B. R. & Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989-999 (1996).
25. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
26. Landsman, R. S., Burkey, T. H., Consroe, P., Roeske, W. R. & Yamamura, H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334, R1-R2 (1997).
27. Stella, N., Schweitzer, P. & Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778 (1997).
28. Giuffrida, A. & Piomelli, D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Lett. 422, 373-376 (1998).
29. Jaggar, S. I., Hasnie, F. S., Sellatwray, S. & Rice, A. S. C. The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain (in the press).